Chemours Stock Price, Forecast & Analysis (NYSE:CC)

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours declared a quarterly dividend on Wednesday, October 30th. Investors of record on Friday, November 15th will be given a dividend of $0.25 per share on Monday, December 16th. This represents a $1.00 annualized dividend and a dividend yield of 5.43%. The ex-dividend date of this dividend is Thursday, November 14th. View Chemours' Dividend History.

Chemours announced that its board has approved a stock repurchase plan on Monday, December 4th 2017, which allows the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

Chemours Co (NYSE:CC) issued its earnings results on Monday, November, 4th. The specialty chemicals company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.03. The specialty chemicals company had revenue of $1.39 billion for the quarter, compared to analyst estimates of $1.40 billion. Chemours had a net margin of 7.24% and a return on equity of 58.38%. The business's revenue for the quarter was down 14.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.49 earnings per share. View Chemours' Earnings History.

Chemours is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Chemours.

Chemours issued an update on its FY19 earnings guidance on Monday, November, 4th. The company provided earnings per share guidance of $2.37-3.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.47.

13 Wall Street analysts have issued 1-year price objectives for Chemours' stock. Their forecasts range from $14.50 to $52.00. On average, they anticipate Chemours' share price to reach $27.14 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price. View Analyst Price Targets for Chemours.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chemours.

News articles about CC stock have trended very negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chemours earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Chemours.

Chemours saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 13,710,000 shares, an increase of 9.2% from the September 15th total of 12,560,000 shares. Based on an average daily volume of 3,460,000 shares, the days-to-cover ratio is currently 4.0 days. Approximately 8.5% of the company's stock are sold short. View Chemours' Current Options Chain.

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Ingevity (NGVT), Balchem (BCPC), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), DowDuPont (DWDP), AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Intel (INTC) and Pfizer (PFE).

Chemours' stock is owned by a number of of retail and institutional investors. Top institutional investors include DNB Asset Management AS (0.39%), Retirement Systems of Alabama (0.36%), Selz Capital LLC (0.34%), Alberta Investment Management Corp (0.30%), Rhumbline Advisers (0.26%) and California Public Employees Retirement System (0.21%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, Christian W Siemer, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View Institutional Ownership Trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including Teacher Retirement System of Texas, Gateway Investment Advisers LLC, Selz Capital LLC, Great West Life Assurance Co. Can, Zurcher Kantonalbank Zurich Cantonalbank, Nisa Investment Advisors LLC, Brookstone Capital Management and Dupont Capital Management Corp. Company insiders that have sold Chemours company stock in the last year include Amy Trojanowski, Mark Newman and Paul Kirsch. View Insider Buying and Selling for Chemours.

CC stock was acquired by a variety of institutional investors in the last quarter, including Alberta Investment Management Corp, Traynor Capital Management Inc., WBI Investments Inc., State of New Jersey Common Pension Fund D, DNB Asset Management AS, Railway Pension Investments Ltd, Investors Research Corp and Pacer Advisors Inc.. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown and Susan M Kelliher. View Insider Buying and Selling for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CC stock can currently be purchased for approximately $18.43.

Chemours has a market capitalization of $3.01 billion and generates $6.64 billion in revenue each year. The specialty chemicals company earns $995 million in net income (profit) each year or $5.67 on an earnings per share basis. Chemours employs 7,000 workers across the globe.View Additional Information About Chemours.

The official website for Chemours is http://www.chemours.com/.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]